Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 9/20 | 1.00 |
| ▸ | ITK | Q08881 | 5/20 | 0.59 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1470097 | 0.97 | ADORA2A (0.93) | ADORA2AITKEHMT2MMP13TP53 | |
| SCHEMBL1467942 | 0.94 | ADORA2A (1.00) | ADORA2AITK | |
| SCHEMBL1468370 | 0.94 | ADORA2A (1.00) | ADORA2AITKEHMT2MMP13TP53 | |
| SCHEMBL1468015 | 0.94 | ADORA2A (1.00) | ADORA2AITKEHMT2MMP13TP53 | |
| SCHEMBL8231257 | 0.94 | ADORA2A (0.89) | ADORA2AITKEHMT2MMP13TP53 | |
| SCHEMBL1468397 | 0.93 | ADORA2A (1.00) | ADORA2AITK | |
| SCHEMBL12744869 | 0.93 | ADORA2A (0.86) | ADORA2AITKEHMT2MMP13TP53 | |
| SCHEMBL1468352 | 0.91 | ADORA2A (0.83) | ADORA2AITKEHMT2TP53MEN1 | |
| SCHEMBL1468300 | 0.90 | ADORA2A (1.00) | ADORA2AITKEHMT2MMP13TP53 | |
| SCHEMBL1468329 | 0.80 | ADORA2A (0.89) | ADORA2AITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2007133983-A2 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | ADORA2A, ADORA2B, ADORA1 | ADORA2A 1/4885ITK 3370/4885EHMT2 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.